6533b831fe1ef96bd1299762

RESEARCH PRODUCT

P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy

Antoine AdenisHarvey J. MamonKyoko KatoToshihiko DoiC. ShihJaafar BennounaByoung Chul ChoPeter C. EnzingerMarkus MoehlerLiang ShenManish A. ShahXiaolong FuAnjali DesaiPooja Bhagia

subject

medicine.medical_specialtybusiness.industryHematologyDefinitive chemoradiotherapyPembrolizumabPlacebomedicine.diseaseGastroenterologyDouble blindOncologyInternal medicineCarcinomaMedicineIn patientbusinesshttps://doi.org/10.1016/j.annonc.2020.04.116